Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Bristol-Myers Squibb
(NY:
BMY
)
43.90
-0.09 (-0.20%)
Official Closing Price
Updated: 7:00 PM EDT, May 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Bristol-Myers Squibb
< Previous
1
2
3
4
5
6
7
8
9
...
41
42
Next >
Analyst Assess Implications of Bristol Myers' Investigational Blood Thinner Post Bayer Trial Setback Amid Shaken Investor Confidence
November 20, 2023
Monday, Bayer AG (OTC: BAYRY) (OTC: BAYZF)
Via
Benzinga
Bayer's Blood Thinner Study Stopped Early Due To Lack Of Efficacy: Details
November 20, 2023
Bayer AG (OTC: BAYRY) (OTC: BAYZF)
Via
Benzinga
Why Bristol Myers Squibb Stock Is Fading Today
November 20, 2023
A high-profile clinical failure by a rival is weighing on the drugmaker's shares today.
Via
The Motley Fool
Dutch Bros (BROS) Stock Gains on JPMorgan Upgrade
November 20, 2023
Dutch Bros stock is getting a boost on Monday after JPMorgan analyst John Ivankoe weighed in on BROS shares with an upgrade.
Via
InvestorPlace
Uber Stock Falls After Announcement of $1.2 Billion Convertible Notes Offering
November 20, 2023
Uber stock is moving on Monday as investors react to a $1.2 billion convertible senior notes offering and plans for the funds.
Via
InvestorPlace
Looking At Bristol-Myers Squibb's Recent Unusual Options Activity
November 17, 2023
Via
Benzinga
The Latest Analyst Ratings for Bristol-Myers Squibb
November 15, 2023
Via
Benzinga
Decoding Bristol-Myers Squibb's Options Activity: What's the Big Picture?
November 09, 2023
Via
Benzinga
Looking At Bristol-Myers Squibb's Recent Unusual Options Activity
October 30, 2023
Via
Benzinga
Why Is Bristol-Myers Squibb (BMY) Stock Down Today?
November 20, 2023
Bristol-Myers Squibb stock is falling on Monday as investors in BMY shares react to two updates weighing on the company's stock.
Via
InvestorPlace
Why Is Pharma Giant Bristol-Myers Squibb Stock Trading Lower Today?
November 20, 2023
Shares of Bristol-Myers Squibb Company (NYSE: BMY) and 2seventy Bio Inc (NASDAQ: TSVT) fell after the companies' efforts to win expanded U.S.
Via
Benzinga
FDA Approves Bristol-Myers' Lung Cancer Drug Acquired Via $4B Turning Point Deal: Competes With Roche, Merck, AstraZeneca
November 16, 2023
The FDA approved Bristol Myers Squibb And Co's (NYSE: BMY) Augtyro (repotrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small
Via
Benzinga
Exposures
Product Safety
Could Bristol-Myers Squibb Stock Help You Retire A Millionaire?
November 16, 2023
It isn't exactly a growth stock, but it has a few features that could make you richer.
Via
The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
November 15, 2023
Via
Benzinga
Is NYSE:BMY suited for dividend investing?
October 30, 2023
Is BRISTOL-MYERS SQUIBB CO (NYSE:BMY) suited for dividend investing?
Via
Chartmill
Apple, AMD, Palantir Earnings On Deck This Week As Market Seeks Positive Catalysts In Fed Decision Week
October 30, 2023
S&P 500 earnings is expected to grow in Q3, reversing a four-quarter slide, as the reporting season enters its third week.
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Bristol Myers Squibb Proved in Q3 Why Its Diverse Portfolio Makes It a Solid Investment
November 14, 2023
The stock isn't nearly as risky as its low valuation suggests.
Via
The Motley Fool
Debt-Fueled Buybacks: 3 Stocks Undeterred by Rising Rates
November 13, 2023
Share repurchases have slowed in 2023, partly due to the 1% tax. Here are three buybacks partially paid for with debt offerings.
Via
InvestorPlace
Merck and Bristol Myers Squibb Will Face Off in This 1 Market -- but Who Will Win?
November 11, 2023
There's a lot more at stake than bragging rights.
Via
The Motley Fool
3 No-Brainer Stocks to Buy With $500 Right Now
November 08, 2023
A reasonably modest amount of money can go a long way when it's invested in time-tested businesses with sustained catalysts.
Via
The Motley Fool
8 Health Care Stocks Whale Activity In Today's Session
November 07, 2023
Via
Benzinga
Christopher Boerner To Take The Helm At Bristol Myers Squibb As Chair Of The Board, CEO
October 31, 2023
Via
Benzinga
Week In Review: Hansoh Sells Ex-China ADC Rights To GSK In $1.6 Billion Deal
October 28, 2023
Hansoh Pharma sold ex-China rights for its B7-H4 ADC to GSK in a $1.57 billion deal. Meanwhile, OrbiMed has raised $4.3 billion in commitments for three healthcare funds, including $751 million for its...
Via
Talk Markets
Pharma Giant Bristol-Myers Stock At 52-Week Low: Analyst Sees Uncertainty In Near-Term Outlook
October 27, 2023
Bristol-Myers Squibb Co (NYSE: BMY) shares are trading lower on continuous weakness following the disappointing Q3 earnings and a downward revision to the
Via
Benzinga
Bristol Myers Squibb Analysts Slash Their Forecasts Following Q3 Results
October 27, 2023
Bristol Myers Squibb & Co (NYSE: BMY) reported better-than-expected earnings for its third quarter.
Via
Benzinga
Stock Market Correction Intensifies; Google, Meta, Microsoft, Amazon Are Big Earnings Movers: Weekly Review
October 27, 2023
Microsoft, Google, Amazon and Meta led big earnings.
Via
Investor's Business Daily
Bristol Myers Squibb (BMY) Q3 2023 Earnings Call Transcript
October 26, 2023
BMY earnings call for the period ending September 30, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
US Stocks Mixed; Bristol Myers Posts Upbeat Earnings
October 26, 2023
U.S. stocks traded mixed this morning, following the release of several economic reports. Following the market opening Thursday, the Dow traded up 0.10% to 33,069.66 while the NASDAQ fell 0.24% to...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Bristol Myers Squibb's Revlimid Sales Plunge 41%, but Opdivo and Eliquis Boost Q3, Stock Dips
October 26, 2023
Bristol Myers Squibb & Co (NYSE: BMY) said that its Q3 revenues of $10.966 billion declined 2% Y/Y, or 3% when adjusted for foreign exchange, due to lower sales of Revlimid, partially offset by in-line...
Via
Benzinga
Bristol Myers Skids 5% After Pushing Back A Key Sales Milestone By A Year
October 26, 2023
The company expects its new drugs to reach $10 billion in sales by 2026.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
9
...
41
42
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.